newsfilter
← Latest News
ACCESS Newswire·

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional